XTX Topco Ltd Has $95,000 Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

XTX Topco Ltd lifted its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 51.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 49,290 shares of the company’s stock after purchasing an additional 16,687 shares during the quarter. XTX Topco Ltd owned about 0.06% of Tenaya Therapeutics worth $95,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. SG Americas Securities LLC acquired a new position in shares of Tenaya Therapeutics in the third quarter valued at approximately $49,000. The Manufacturers Life Insurance Company boosted its stake in Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares during the period. Algert Global LLC bought a new position in Tenaya Therapeutics during the 2nd quarter worth about $74,000. Walleye Capital LLC acquired a new stake in shares of Tenaya Therapeutics in the 3rd quarter valued at about $134,000. Finally, Panagora Asset Management Inc. bought a new stake in shares of Tenaya Therapeutics in the second quarter valued at about $164,000. 90.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research report on Wednesday. Finally, Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $17.33.

Tenaya Therapeutics Trading Up 18.4 %

NASDAQ TNYA opened at $1.67 on Friday. The firm has a market capitalization of $132.30 million, a P/E ratio of -1.16 and a beta of 2.72. The firm’s fifty day moving average price is $2.43 and its two-hundred day moving average price is $2.69. Tenaya Therapeutics, Inc. has a 1 year low of $0.99 and a 1 year high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. On average, research analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.